Eli Lilly’s weight loss drug Zepbound is set to compete with Novo Nordisk’s Wegovy. Zepbound, approved by the FDA recently, is priced at a 20% discount to Wegovy. The move is part of Lilly’s strategy to broaden access to this class of drugs, particularly among individuals diagnosed with obesity. Clinical trials have suggested that Zepbound might offer better efficacy than Wegovy. Experts expect insurance coverage for these drugs to increase as more therapies enter the market. However, challenges in supply could impact the competitive landscape. Lilly and Novo Nordisk have experienced supply constraints due to high demand, although Lilly aims to double its supply by year-end.
To read more, click here.
[Source: Fierce Biotech, November 9th, 2023]